Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus

NCT01208012 · Completed

Last updated 2026-05-28

This clinical trial tests whether the medication liraglutide improves blood flow in the eyes of adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 44 people

Who can join Ages 30–65 · all sexes

Timeline Started 2010-04 · est. completion 2010-11

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT01208012 ↗

Description as written by the study sponsor.

The trial is a phase IV clinical trial investigating the impact of Liraglutide on endothelial function and microvascular blood flow in 44 patients with type 2 diabetes mellitus aged 30-65 and HbA1c ranging from ≥ 5.5% ≤ 7.0%. The patients will be randomized into two study arms, one arm will be treated with Metformin monotherapy, the second arm will be treated with Metformin and Liraglutide at an increasing dose (0.6 mg/day to 1.8 mg/day.)

Treatments tested

Victoza® also known as Victoza®, Liraglutide Drug

Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks. When arrived at the dosage of 1.8 mg daily and the dose is not tolerated by the patient, the dose of Liraglutide can be decreased.Liraglutide is injected in the subcutaneous tissue once daily

Main thing measured	The difference in increase of retinal blood flow after flicker stimulation of retinal endothelial cells
Sponsor	ikfe-CRO GmbH
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01208012 ↗